Opinion|Videos|October 28, 2024
Genetic Testing in Metastatic Prostate Cancer: Key Insights on Germline and Somatic Mutations
Author(s)Pedro Barata, MD, MSc, FACP
Key Takeaways
- Talazoparib in the TALAPRO-1 trial improved progression-free survival and overall response rates in metastatic prostate cancer with specific genetic alterations.
- Rucaparib in the TRITON3 trial showed superior progression-free survival compared to standard treatments, highlighting its efficacy in targeted patient populations.
Panelists discuss how PARP inhibitor monotherapy trials like TALAPRO-1 (talazoparib) and TRITON-3 (rucaparib) have demonstrated efficacy and safety in treating metastatic prostate cancer patients with homologous recombination repair gene alterations, providing important insights into targeted therapy options for this specific patient population.
Advertisement
Episodes in this series
Video Content above is prompted by the following:
- Discuss efficacy and safety findings from monotherapy trials of PARP inhibitors in metastatic prostate cancer harboring homologous recombination repair (gene alterations.
- TALAPRO-1 trial (talazoparib), NCT03148795
- TRITON3 trial (rucaparib), NCT02975934.
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5